AXADIA - AFNET 8

Quick access

AXADIA:

A Safety Study Assessing Oral Anticoagulation with Apixaban versus Vitamin-K Antagonists in Patients with Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment

 

 

PATIENTS

Recruitment was stopped on the 31th of May 2022.
 

97 patients randomised
22 sites open 
 

 

 

 

108

Planned number of patients


 

PARTICIPATING COUNTRIES

 

Germany

 

PUBLICATIONS

Reinecke H, Jürgensmeyer S, Engelbertz C, et al. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. BMJ Open 2018 Sep 10;8:e022690. doi: 10.1136/bmjopen-2018-022690

 

Co-ordinating Investigator Cardiology/ Head of the Trial:
Holger Reinecke, MD, University Hospital, Münster, Germany

Co-ordinating Investigator Nephrology/ Chief Investigator:
Christoph Wanner, MD, University Hospital Würzburg, Germany

 

Overall Responsibility

Legal Sponsor according to the EU directive 2001/ 20/ EC:

Atrial Fibrillation NETwork (AFNET), Münster, Germany

Registration

ClinicalTrials.gov: NCT02933697

EudraCT Nummer: 2015-005503-84